These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 26807894)

  • 1. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer.
    Perez-Lopez R; Lorente D; Blackledge MD; Collins DJ; Mateo J; Bianchini D; Omlin A; Zivi A; Leach MO; de Bono JS; Koh DM; Tunariu N
    Radiology; 2016 Jul; 280(1):151-60. PubMed ID: 26807894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.
    Perez-Lopez R; Mateo J; Mossop H; Blackledge MD; Collins DJ; Rata M; Morgan VA; Macdonald A; Sandhu S; Lorente D; Rescigno P; Zafeiriou Z; Bianchini D; Porta N; Hall E; Leach MO; de Bono JS; Koh DM; Tunariu N
    Radiology; 2017 Apr; 283(1):168-177. PubMed ID: 27875103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
    Armstrong AJ; Kaboteh R; Carducci MA; Damber JE; Stadler WM; Hansen M; Edenbrandt L; Forsberg G; Nordle Ö; Pili R; Morris MJ
    Urol Oncol; 2014 Nov; 32(8):1308-16. PubMed ID: 25240761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel.
    Uemura K; Miyoshi Y; Kawahara T; Ryosuke J; Yamashita D; Yoneyama S; Yokomizo Y; Kobayashi K; Kishida T; Yao M; Uemura H
    BMC Cancer; 2018 May; 18(1):501. PubMed ID: 29716525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flare phenomenon visualized by
    Zhang X; Nakajima K; Mizokami A; Horikoshi H; Nishimoto K; Hashine K; Matsuyama H; Takahashi S; Wakabayashi H; Kinuya S
    Ann Nucl Med; 2024 Jun; 38(6):428-440. PubMed ID: 38478154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.
    Uemura K; Miyoshi Y; Kawahara T; Yoneyama S; Hattori Y; Teranishi J; Kondo K; Moriyama M; Takebayashi S; Yokomizo Y; Yao M; Uemura H; Noguchi K
    BMC Cancer; 2016 Feb; 16():109. PubMed ID: 26883015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing Radiographic Response to
    Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
    J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    van Steenbergen TRF; Smits M; Scheenen TWJ; van Oort IM; Nagarajah J; Rovers MM; Mehra N; Fütterer JJ
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):147-154. PubMed ID: 31444628
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
    J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.
    Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ
    Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment.
    Frantellizzi V; Pani A; Ippoliti MD; Farcomeni A; Aloise I; Colosi M; Polito C; Pani R; Vincentis G
    Radiol Oncol; 2019 Dec; 54(1):40-47. PubMed ID: 31855572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
    Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
    JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
    Poulsen MH; Rasmussen J; Edenbrandt L; Høilund-Carlsen PF; Gerke O; Johansen A; Lund L
    BJU Int; 2016 May; 117(5):748-53. PubMed ID: 25906907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer.
    Yoshida S; Takahara T; Ishii C; Arita Y; Waseda Y; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Fujii Y
    Clin Genitourin Cancer; 2020 Aug; 18(4):e391-e396. PubMed ID: 31902713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Value of Quantitative Bone SPECT/CT Before
    Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
    J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer.
    Parker SJ; Pond GR; Agarwal N; Alex A; Heilbrun ME; Sonpavde G
    Clin Genitourin Cancer; 2017 Feb; 15(1):53-59. PubMed ID: 27338517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
    Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223.
    Naito M; Ukai R; Hashimoto K
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1203. PubMed ID: 32721117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
    Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
    BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment.
    Fukai S; Daisaki H; Umeda T; Shimada N; Terauchi T; Koizumi M
    Ann Nucl Med; 2024 Jun; 38(6):450-459. PubMed ID: 38517659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.